Omadacycline - Paratek Pharmaceuticals

Drug Profile

Omadacycline - Paratek Pharmaceuticals

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; PTK-0796; ZL 2401

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Merck & Co; Paratek Pharmaceuticals
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Community-acquired pneumonia; Skin and soft tissue infections
  • Phase II Urinary tract infections
  • Preclinical Acute sinusitis; Respiratory tract infections
  • Research Anthrax; Plague
  • No development reported Nosocomial infections

Most Recent Events

  • 20 Jun 2018 Paratek Pharmaceuticals announces a meeting of the Antimicrobial Drugs Advisory Committee of the USFDA scheduled for August 8, 2018 to review the company's New Drug Applications for omadacycline
  • 11 Jun 2018 Efficacy data from two phase III OASIS-1 and OASIS-2 trial in Skin and soft tissue infections released by Paratek Pharmaceuticals
  • 09 May 2018 Paratek Pharmaceuticals plans to launch omadacycline in Community-acquired pneumonia and Skin and soft tissue infections in USA in the first quarter 2019 (PO and IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top